KR102588627B1 - Mast4 유전자를 이용한 세포외 기질 생산용 조성물 및 그 제조방법 - Google Patents

Mast4 유전자를 이용한 세포외 기질 생산용 조성물 및 그 제조방법 Download PDF

Info

Publication number
KR102588627B1
KR102588627B1 KR1020180027111A KR20180027111A KR102588627B1 KR 102588627 B1 KR102588627 B1 KR 102588627B1 KR 1020180027111 A KR1020180027111 A KR 1020180027111A KR 20180027111 A KR20180027111 A KR 20180027111A KR 102588627 B1 KR102588627 B1 KR 102588627B1
Authority
KR
South Korea
Prior art keywords
ser
pro
leu
glu
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020180027111A
Other languages
English (en)
Korean (ko)
Other versions
KR20180103015A (ko
Inventor
김성진
정한성
사토루 다카하시
Original Assignee
김성진
김새롬
김영원
김잎새
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 김성진, 김새롬, 김영원, 김잎새 filed Critical 김성진
Priority to EP18764604.7A priority Critical patent/EP3594324A4/en
Priority to CN201880030519.0A priority patent/CN110612348B/zh
Priority to US16/492,477 priority patent/US11180573B2/en
Priority to JP2019571194A priority patent/JP7154238B2/ja
Priority to CA3055729A priority patent/CA3055729A1/en
Priority to AU2018231559A priority patent/AU2018231559A1/en
Priority to PCT/KR2018/002763 priority patent/WO2018164507A2/ko
Publication of KR20180103015A publication Critical patent/KR20180103015A/ko
Priority to US17/494,765 priority patent/US20220220221A1/en
Priority to JP2022159928A priority patent/JP7498239B2/ja
Priority to AU2023222944A priority patent/AU2023222944A1/en
Application granted granted Critical
Publication of KR102588627B1 publication Critical patent/KR102588627B1/ko
Priority to JP2024087859A priority patent/JP2024116197A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0655—Chondrocytes; Cartilage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C12N15/1031—Mutagenizing nucleic acids mutagenesis by gene assembly, e.g. assembly by oligonucleotide extension PCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0656—Adult fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11001—Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/65—MicroRNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020180027111A 2017-03-08 2018-03-07 Mast4 유전자를 이용한 세포외 기질 생산용 조성물 및 그 제조방법 Active KR102588627B1 (ko)

Priority Applications (11)

Application Number Priority Date Filing Date Title
AU2018231559A AU2018231559A1 (en) 2017-03-08 2018-03-08 Extracellular matrix-producing composition using MAST4 gene and preparation method therefor
CN201880030519.0A CN110612348B (zh) 2017-03-08 2018-03-08 用于使用mast4基因产生细胞外基质的组合物及其制备方法
US16/492,477 US11180573B2 (en) 2017-03-08 2018-03-08 Extracellular matrix-producing composition using MAST4 gene and preparation method therefor
JP2019571194A JP7154238B2 (ja) 2017-03-08 2018-03-08 Ｍａｓｔ４遺伝子を利用した細胞外基質生産用組成物及びその製造方法
CA3055729A CA3055729A1 (en) 2017-03-08 2018-03-08 Extracellular matrix-producing composition using mast4 gene and preparation method therefor
PCT/KR2018/002763 WO2018164507A2 (ko) 2017-03-08 2018-03-08 Mast4 유전자를 이용한 세포외 기질 생산용 조성물 및 그 제조방법
EP18764604.7A EP3594324A4 (en) 2017-03-08 2018-03-08 EXTRACELLULAR MATRIX-PRODUCING COMPOSITION WITH MAST4-GEN AND MANUFACTURING METHOD FOR IT
US17/494,765 US20220220221A1 (en) 2017-03-08 2021-10-05 Extracellular matrix-producing composition using mast4 gene and preparation method therefor
JP2022159928A JP7498239B2 (ja) 2017-03-08 2022-10-04 Ｍａｓｔ４遺伝子を利用した細胞外基質生産用組成物及びその製造方法
AU2023222944A AU2023222944A1 (en) 2017-03-08 2023-08-31 Extracellular matrix-producing composition using MAST4 gene and preparation method therefor
JP2024087859A JP2024116197A (ja) 2017-03-08 2024-05-30 Ｍａｓｔ４遺伝子を利用した細胞外基質生産用組成物及びその製造方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020170029607 2017-03-08
KR20170029607 2017-03-08

Publications (2)

Publication Number Publication Date
KR20180103015A KR20180103015A (ko) 2018-09-18
KR102588627B1 true KR102588627B1 (ko) 2023-10-16

Family

ID=63718648

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020180027111A Active KR102588627B1 (ko) 2017-03-08 2018-03-07 Mast4 유전자를 이용한 세포외 기질 생산용 조성물 및 그 제조방법

Country Status (7)

Country Link
US (2) US11180573B2 (enExample)
EP (1) EP3594324A4 (enExample)
JP (3) JP7154238B2 (enExample)
KR (1) KR102588627B1 (enExample)
CN (1) CN110612348B (enExample)
AU (2) AU2018231559A1 (enExample)
CA (1) CA3055729A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021146566A1 (en) * 2020-01-16 2021-07-22 The Johns Hopkins University Engineered fibroblasts as cell therapy to treat cancer via tumor stroma stabilization
US20240299579A1 (en) * 2020-07-23 2024-09-12 Orthobio Therapeutics, Inc. Gene editing to improve joint function
US20250136991A1 (en) * 2022-02-04 2025-05-01 Kim Seong Jin Method of making bone and cartilage

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140341887A1 (en) 2009-09-03 2014-11-20 Genentech, Inc. Methods for treating, diagnosing, and monitoring rheumatoid arthritis
WO2015035395A1 (en) 2013-09-09 2015-03-12 Figene, Llc Gene therapy for the regeneration of chondrocytes or cartilage type cells

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055298A (en) * 1987-12-01 1991-10-08 Chemisches Laboratorium Dr. Kurt Richter Gmbh Cosmetic composition comprising an extracellular connective tissue matrix
US6528052B1 (en) * 2000-09-29 2003-03-04 The Board Of Trustees Of The Leland Stanford Junior University Method for in vivo ex vivo and in vitro repair and regeneration of cartilage and collagen and bone remodeling
US20060153797A1 (en) * 2004-06-11 2006-07-13 Bortolotto Susan K Tissue material and matrix
KR100614903B1 (ko) * 2004-08-06 2006-08-25 테고사이언스 (주) 케라티노사이트 및/또는 섬유아세포를 함유하는 화장용조성물
EP1894581A1 (en) * 2006-08-31 2008-03-05 CellCoTec B.V. Repair of cartilage tissue using a matrix gel containing chondrocytes
CA2719981A1 (en) * 2008-03-31 2009-10-08 Scarcell Therapeutics Method for the cosmetic treatment of skin ageing
US10301620B2 (en) * 2010-12-22 2019-05-28 Murdoch Childrens Research Institute Method of treatment
EP2753692B1 (en) * 2011-09-07 2019-03-27 3-D Matrix Ltd. Microrna-based methods and assays for osteosarcoma
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
KR102039311B1 (ko) 2012-09-07 2019-11-04 주식회사 마크로젠 Ａｘｌ을 포함하는 융합 단백질 및 이를 포함하는 암 진단용 조성물
CA2930556A1 (en) * 2013-11-14 2015-05-21 Dermarche Labs, Llc Fibroblast mixtures and methods of making and using the same
CA2986441A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
AU2017207445B2 (en) * 2016-01-14 2023-12-07 Spinalcyte, Llc Cellular blend for the regeneration of chondrocytes or cartilage type cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140341887A1 (en) 2009-09-03 2014-11-20 Genentech, Inc. Methods for treating, diagnosing, and monitoring rheumatoid arthritis
WO2015035395A1 (en) 2013-09-09 2015-03-12 Figene, Llc Gene therapy for the regeneration of chondrocytes or cartilage type cells
US20160220699A1 (en) 2013-09-09 2016-08-04 Figene, Llc Gene therapy for the regeneration of chondrocytes or cartilage type cells

Also Published As

Publication number Publication date
JP7498239B2 (ja) 2024-06-11
JP2024116197A (ja) 2024-08-27
JP2020513849A (ja) 2020-05-21
AU2023222944A1 (en) 2023-11-23
EP3594324A4 (en) 2021-01-20
AU2018231559A1 (en) 2019-10-31
EP3594324A2 (en) 2020-01-15
JP7154238B2 (ja) 2022-10-17
JP2022188178A (ja) 2022-12-20
CN110612348A (zh) 2019-12-24
CN110612348B (zh) 2024-02-09
KR20180103015A (ko) 2018-09-18
US20220220221A1 (en) 2022-07-14
US20200239596A1 (en) 2020-07-30
CA3055729A1 (en) 2018-09-13
US11180573B2 (en) 2021-11-23

Similar Documents

Publication Publication Date Title
AU2022201296B2 (en) Genetically modified cells, tissues, and organs for treating disease
AU2020270508B2 (en) C/EBP alpha short activating RNA compositions and methods of use
CN114176043B (zh) 用于治疗疾病的遗传修饰的细胞、组织和器官
KR20210116526A (ko) 증진된 항-신생물 활성 및 면역억제 내성을 갖는 변형된 면역 세포
KR20210060429A (ko) 적응 면역의 조절을 위한 조성물 및 방법
AU2023222944A1 (en) Extracellular matrix-producing composition using MAST4 gene and preparation method therefor
CN110088272A (zh) 用于将细胞重编程为树突状细胞或抗原呈递细胞的组合物、其方法和用途
KR101791770B1 (ko) 단백질의 제조 방법
KR101760618B1 (ko) Sox 유전자가 이입된 비바이러스성 미니써클 벡터 및 이의 제조방법
KR102672646B1 (ko) 암세포의 부착 의존성 변환을 통한 암 전이 억제 방법
KR20180021135A (ko) 인간화 심장 근육
KR102443932B1 (ko) 세포의 부착 의존성 조절용 조성물
WO2018164507A2 (ko) Mast4 유전자를 이용한 세포외 기질 생산용 조성물 및 그 제조방법

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R19-X000 Request for party data change rejected

St.27 status event code: A-3-3-R10-R19-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

PE0801 Dismissal of amendment

St.27 status event code: A-2-2-P10-P12-nap-PE0801

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301